The following antibodies were used: anti-Nrf2 (monoclonal, 1:1000, Santa Cruz)
Research note: A 2025 literature and patent review catalogued BPC-157's multifunctional activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular preclinical models
The apoptosis involved in SIMI encompasses the activation or inhibition of multiple pathways, including TNF- and MAPK-related, PI3K/AKT/mTOR, and NF-B signaling pathways, with the release of various inflammatory factors that directly lead to myocardial damage, resulting in increased secretion of inducible NO synthase and excessive production of NO (98,104)
Contrave produced greater improvements in various cardiometabolic risk markers, participant-reported weight-related quality of life, and eating control